Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
24 08 2020
Historique:
received: 14 04 2020
accepted: 22 05 2020
pubmed: 5 6 2020
medline: 24 6 2021
entrez: 5 6 2020
Statut: epublish

Résumé

We compared titers of antibodies against A/H1N1, A/H3N2, and B influenza virus strains collected pre- and postvaccination using hemagglutination inhibition (HI) and microneutralization (MN) assays and data from two vaccine trials: study 1, performed with a cell-grown trivalent influenza vaccine (TIVc) using cell-grown target virus in both assays, and study 2, performed with an egg-grown adjuvanted quadrivalent influenza vaccine (aQIVe) using egg-grown target virus. The relationships between HI- and MN-derived log-transformed titers were examined using different statistical techniques. Deming regression analyses showed point estimates for slopes generally close to 1 across studies and strains. The slope of regression was closest to 1 for A/H3N2 strain when either cell- or egg-grown viral target virus was used. Bland-Altman plots indicated a very small percentage of results outside 2 and 3 standard deviations. The magnitudes and directions of differences between titers in the two assays varied by study and strain. Mean differences favored the MN assay for A/H1N1 and B strains in study 1, whereas the titers determined by HI were higher than those determined by MN against the A/H3N2 strain. In study 2, mean differences favored the MN assay for A/H3N2 and B strains. Overall, the directions and magnitudes of the mean differences were similar between the two vaccines. The concordance correlation coefficient values ranged from 0.74 (A/H1N1 strain, study 1) to 0.97 (A/H3N2 strain, study 1). The comparative analysis demonstrates an overall strong positive correlation between the HI and MN assays. These data support the use of the MN assay to quantify the immune response of influenza vaccines in clinical studies, particularly for the A/H3N2 strain.

Identifiants

pubmed: 32493784
pii: JCM.00750-20
doi: 10.1128/JCM.00750-20
pmc: PMC7448638
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 Heeringa et al.

Références

J Gen Virol. 1992 May;73 ( Pt 5):1159-65
pubmed: 1588320
Hum Vaccin Immunother. 2015;11(5):1223-34
pubmed: 25875691
Influenza Other Respir Viruses. 2015 Nov;9(6):331-340
pubmed: 26073976
Stat Methods Med Res. 1999 Jun;8(2):135-60
pubmed: 10501650
J Infect Dis. 1989 Aug;160(2):191-8
pubmed: 2760480
Clin Chem. 1993 Mar;39(3):424-32
pubmed: 8448852
J Hyg (Lond). 1972 Dec;70(4):767-77
pubmed: 4509641
J Clin Microbiol. 2011 Jun;49(6):2210-5
pubmed: 21471339
PLoS One. 2015 Jun 24;10(6):e0131531
pubmed: 26107625
J Immunol. 1962 Jun;88:788-95
pubmed: 13882798
Vet Microbiol. 1995 Jun;45(1):81-92
pubmed: 7653031
Vaccine. 2014 Aug 20;32(37):4713-25
pubmed: 24582632
J Infect Dis. 2013 Oct 15;208(8):1320-4
pubmed: 23908481
Vaccines (Basel). 2014 Oct 13;2(4):707-34
pubmed: 26344888
J Biopharm Stat. 2008;18(1):126-44
pubmed: 18161545
Lancet Respir Med. 2018 May;6(5):345-356
pubmed: 29631857
J Gen Virol. 2017 Jun;98(6):1274-1281
pubmed: 28612701
Pediatr Infect Dis J. 2011 Dec;30(12):1081-5
pubmed: 21983214
Influenza Other Respir Viruses. 2018 Nov;12(6):675-686
pubmed: 30019448
Influenza Other Respir Viruses. 2017 May;11(3):283-288
pubmed: 28218983
J Clin Microbiol. 2014 May;52(5):1672-7
pubmed: 24622097
J Clin Microbiol. 1982 Apr;15(4):660-2
pubmed: 7040463
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
Biotechnol J. 2014 Mar;9(3):405-14
pubmed: 24323790
Vaccine. 2017 Jan 3;35(1):46-52
pubmed: 27899226
Vaccine. 2014 Nov 12;32(48):6583-90
pubmed: 24975811
Influenza Other Respir Viruses. 2016 Nov;10(6):518-524
pubmed: 27406695

Auteurs

Marten Heeringa (M)

Clinical Development, Seqirus Netherlands B.V., Amsterdam, the Netherlands marten.heeringa@Seqirus.com.

Brett Leav (B)

Clinical Development, Seqirus Inc., Cambridge, Massachusetts, USA.

Igor Smolenov (I)

Clinical Development, Seqirus Inc., Cambridge, Massachusetts, USA.

Giuseppe Palladino (G)

Clinical Development, Seqirus Inc., Cambridge, Massachusetts, USA.

Leah Isakov (L)

Clinical Development, Seqirus Inc., Cambridge, Massachusetts, USA.

Vincent Matassa (V)

Research and Development, Seqirus Australia Pty Ltd., Parkville, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH